Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 8/20 | 0.42 |
| ▸ | HTT | P42858 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435911 | 0.90 | KDM4E (0.45) | KDM4ELMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12435929 | 0.89 | KDM4E (0.44) | KDM4ELMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12435917 | 0.88 | MAPT (0.44) | KDM4ELMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12435931 | 0.85 | KDM4E (0.40) | KDM4ELMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12435922 | 0.83 | ATM (0.51) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL12435925 | 0.83 | KDM4E (0.40) | KDM4ELMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12435918 | 0.83 | KMT2A (0.43) | LMNAALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL12435927 | 0.83 | LMNA (0.43) | LMNAHTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL17507493 | 0.78 | HTT (0.51) | KDM4ELMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL12435959 | 0.78 | ATM (0.47) | LMNASMN1; SMN2ALDH1A1MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178108-A1 | Group of amino substituted benzoyl derivatives and their preparation and their use | Institute of Medicinal Biotechnology Academy of Medical Science (CN) | 2011-07-21 | — | — | US | disclosed |
| US-20110178108-A1 | Group of amino substituted benzoyl derivatives and their preparation and their use | Institute of Medicinal Biotechnology Academy of Medical Science (CN) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178108-A1 | Group of amino substituted benzoyl derivatives and their preparation and their use | CUL3, APOBEC3G, BRPF3 | KDM4E 368/4885LMNA 2812/4885HTT 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.